Spencer Ryan

Spencer Ryan, CEO and director of Dynavax Technologies (DVAX), has not made a single open-market purchase or sale of company stock in his 38 reported Form 4 transactions. His entire footprint is mechanical: equity grants (code A), option exercises (code M), and shares withheld to cover taxes (code F). The largest dollar movement came on December 24, 2025, when $2.13 million in DVAX shares were surrendered to cover tax obligations following an option exercise the prior day—an automatic process, not a discretionary trade. A smaller $472,307 tax-withholding event occurred on February 18, 2025, alongside another option exercise. The most recent cluster of filings, dated February 10, 2026, consists almost entirely of code D transactions—sales back to the issuer at zero value—plus two code A grants and one code U (unspecified) entry. These carry no monetary signal. Notably, Ryan’s only other company involvement is Cidara Therapeutics (CDTX), where three code D filings appeared on January 7, 2026, also at zero value. Across all filings, total acquired value is just $3,798.90, and both buy and sell totals are zero. The pattern reveals a compensation-driven insider, not a conviction trader. Ryan accumulates shares through scheduled awards and exercises, then immediately cedes a portion to tax withholding. There is no directional bias—no accumulation beyond grants, no trimming beyond mandatory surrenders. For investors parsing Form 4s for signal, Ryan’s activity is noise: administrative, predictable, and devoid of discretionary market timing.